Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial

FA. Wijburg, B. Bénichou, DG. Bichet, LA. Clarke, G. Dostalova, A. Fainboim, A. Fellgiebel, C. Forcelini, K. An Haack, RJ. Hopkin, M. Mauer, B. Najafian, CR. Scott, SP. Shankar, BL. Thurberg, C. Tøndel, A. Tylki-Szymańska, U. Ramaswami,

. 2015 ; 10 (5) : e0124987. [pub] 20150508

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010220

TRIAL DESIGN: This analysis characterizes the degree of early organ involvement in a cohort of oligo-symptomatic untreated young patients with Fabry disease enrolled in an ongoing randomized, open-label, parallel-group, phase 3B clinical trial. METHODS: Males aged 5-18 years with complete α-galactosidase A deficiency, without symptoms of major organ damage, were enrolled in a phase 3B trial evaluating two doses of agalsidase beta. Baseline disease characteristics of 31 eligible patients (median age 12 years) were studied, including cellular globotriaosylceramide (GL-3) accumulation in skin (n = 31) and kidney biopsy (n = 6; median age 15 years; range 13-17 years), renal function, and glycolipid levels (plasma, urine). RESULTS: Plasma and urinary GL-3 levels were abnormal in 25 of 30 and 31 of 31 patients, respectively. Plasma lyso-GL-3 was elevated in all patients. GL-3 accumulation was documented in superficial skin capillary endothelial cells (23/31 patients) and deep vessel endothelial cells (23/29 patients). The mean glomerular filtration rate (GFR), measured by plasma disappearance of iohexol, was 118.1 mL/min/1.73 m(2) (range 90.4-161.0 mL/min/1.73 m(2)) and the median urinary albumin/creatinine ratio was 10 mg/g (range 4.0-27.0 mg/g). On electron microscopy, renal biopsy revealed GL-3 accumulation in all glomerular cell types (podocytes and parietal, endothelial, and mesangial cells), as well as in peritubular capillary and non-capillary endothelial, interstitial, vascular smooth muscle, and distal tubules/collecting duct cells. Lesions indicative of early Fabry arteriopathy and segmental effacement of podocyte foot processes were found in all 6 patients. CONCLUSIONS: These data reveal that in this small cohort of children with Fabry disease, histological evidence of GL-3 accumulation, and cellular and vascular injury are present in renal tissues at very early stages of the disease, and are noted before onset of microalbuminuria and development of clinically significant renal events (e.g. reduced GFR). These data give additional support to the consideration of early initiation of enzyme replacement therapy, potentially improving long-term outcome. TRIAL REGISTRATION: ClinicalTrials.gov NCT00701415.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010220
003      
CZ-PrNML
005      
20160408112302.0
007      
ta
008      
160408s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0124987 $2 doi
024    7_
$a 10.1371/journal.pone.0124987 $2 doi
035    __
$a (PubMed)25955246
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wijburg, Frits A $u Academic Medical Center, University Hospital of Amsterdam, Amsterdam, The Netherlands.
245    10
$a Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial / $c FA. Wijburg, B. Bénichou, DG. Bichet, LA. Clarke, G. Dostalova, A. Fainboim, A. Fellgiebel, C. Forcelini, K. An Haack, RJ. Hopkin, M. Mauer, B. Najafian, CR. Scott, SP. Shankar, BL. Thurberg, C. Tøndel, A. Tylki-Szymańska, U. Ramaswami,
520    9_
$a TRIAL DESIGN: This analysis characterizes the degree of early organ involvement in a cohort of oligo-symptomatic untreated young patients with Fabry disease enrolled in an ongoing randomized, open-label, parallel-group, phase 3B clinical trial. METHODS: Males aged 5-18 years with complete α-galactosidase A deficiency, without symptoms of major organ damage, were enrolled in a phase 3B trial evaluating two doses of agalsidase beta. Baseline disease characteristics of 31 eligible patients (median age 12 years) were studied, including cellular globotriaosylceramide (GL-3) accumulation in skin (n = 31) and kidney biopsy (n = 6; median age 15 years; range 13-17 years), renal function, and glycolipid levels (plasma, urine). RESULTS: Plasma and urinary GL-3 levels were abnormal in 25 of 30 and 31 of 31 patients, respectively. Plasma lyso-GL-3 was elevated in all patients. GL-3 accumulation was documented in superficial skin capillary endothelial cells (23/31 patients) and deep vessel endothelial cells (23/29 patients). The mean glomerular filtration rate (GFR), measured by plasma disappearance of iohexol, was 118.1 mL/min/1.73 m(2) (range 90.4-161.0 mL/min/1.73 m(2)) and the median urinary albumin/creatinine ratio was 10 mg/g (range 4.0-27.0 mg/g). On electron microscopy, renal biopsy revealed GL-3 accumulation in all glomerular cell types (podocytes and parietal, endothelial, and mesangial cells), as well as in peritubular capillary and non-capillary endothelial, interstitial, vascular smooth muscle, and distal tubules/collecting duct cells. Lesions indicative of early Fabry arteriopathy and segmental effacement of podocyte foot processes were found in all 6 patients. CONCLUSIONS: These data reveal that in this small cohort of children with Fabry disease, histological evidence of GL-3 accumulation, and cellular and vascular injury are present in renal tissues at very early stages of the disease, and are noted before onset of microalbuminuria and development of clinically significant renal events (e.g. reduced GFR). These data give additional support to the consideration of early initiation of enzyme replacement therapy, potentially improving long-term outcome. TRIAL REGISTRATION: ClinicalTrials.gov NCT00701415.
650    _2
$a mladiství $7 D000293
650    _2
$a biopsie $7 D001706
650    _2
$a mozek $x patologie $7 D001921
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a demografie $7 D003710
650    _2
$a cévní endotel $x patologie $7 D004730
650    _2
$a Fabryho nemoc $x krev $x farmakoterapie $x patofyziologie $x moč $7 D000795
650    _2
$a genotyp $7 D005838
650    _2
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a glykolipidy $x krev $7 D006017
650    _2
$a lidé $7 D006801
650    _2
$a johexol $7 D007472
650    _2
$a ledviny $x patologie $x patofyziologie $x ultrastruktura $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a kvalita života $7 D011788
650    _2
$a kůže $x krevní zásobení $7 D012867
650    _2
$a sfingolipidy $x krev $7 D013107
650    _2
$a trihexosylceramidy $x krev $x genetika $x moč $7 D014281
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bénichou, Bernard $u Genzyme Europe, Saint-Germain-en-Laye, France.
700    1_
$a Bichet, Daniel G $u Hôpital du Sacré-Cœur de Montréal and University of Montreal, Montreal, QC, Canada.
700    1_
$a Clarke, Lorne A $u University of British Columbia, Child and Family Research Institute, Vancouver, BC, Canada.
700    1_
$a Dostalova, Gabriela $u Charles University Prague, General University Hospital Prague, Prague, Czech Republic.
700    1_
$a Fainboim, Alejandro $u Hospital de Niños Ricardo Gutierrez, Hospital de Día Polivalente, Ciudad Autónoma de Buenos Aires, Argentina.
700    1_
$a Fellgiebel, Andreas $u University Medical Center Mainz, Mainz, Germany.
700    1_
$a Forcelini, Cassiano $u Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil.
700    1_
$a An Haack, Kristina $u Sanofi, Chilly-Mazarin, France. $7 gn_A_00005786
700    1_
$a Hopkin, Robert J $u Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
700    1_
$a Mauer, Michael $u Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America.
700    1_
$a Najafian, Behzad $u Department of Pathology, University of Washington, Seattle, Washington, United States of America.
700    1_
$a Scott, C Ronald $u University of Washington School of Medicine, Seattle, Washington, United States of America.
700    1_
$a Shankar, Suma P $u Emory University School of Medicine, Decatur, Georgia, United States of America.
700    1_
$a Thurberg, Beth L $u Department of Pathology, Genzyme, Framingham, Massachusetts, United States of America.
700    1_
$a Tøndel, Camilla $u Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
700    1_
$a Tylki-Szymańska, Anna $u Klinika Pediatrii, Żywienia i Chorób Metabolicznych Instytut "Pomnik - Centrum Zdrowia Dziecka", Warsaw, Poland.
700    1_
$a Ramaswami, Uma $u Royal Free Hospital, London, United Kingdom.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 5 (2015), s. e0124987
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25955246 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160408112341 $b ABA008
999    __
$a ok $b bmc $g 1113649 $s 934588
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 5 $d e0124987 $e 20150508 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace